Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...7273747576777879808182...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Bone effects of bisphosphonates and denosumab treatments in breast or prostate cancer (Pubmed Central) -  Apr 30, 2019   
    In addition, adjuvant bisphosphonates may be associated with benefits on disease free survival, especially regarding bone recurrences, in postmenopausal women with non-metastatic breast cancer. In the presence of bone metastases, inhibitors of bone resorption at higher doses and frequencies prevent SRE.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Management of multiple myeloma bone disease: impact of treatment on renal function. (Pubmed Central) -  Apr 28, 2019   
    The exact mechanism by which BPs cause renal impairment is yet to be elucidated. Another promising agent is denosumab, a RANKL inhibitor, which can be administrated regardless of renal function and does not need the relevant dose-adjustments.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Perjeta (pertuzumab) / Roche
    Review, Journal:  What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology? (Pubmed Central) -  Apr 27, 2019   
    We are expecting not only more biosimilar versions of the top 3 blockbuster monoclonal antibodies, trastuzumab, rituximab and bevacizumab, to enter the market; as patent expiration of multiple other cancer biologicals will occur in the next few years, the biosimilar landscape will become much more diversified. Several biosimilars of monoclonal antibodies used in targeted therapy such as cetuximab, pertuzumab, or denosumab are in early development.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Observational data, Journal:  An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. (Pubmed Central) -  Apr 26, 2019   
    Among patients with prostate cancer treated in the United States, most of those treated with an emerging therapy between 2013 and 2015 also received denosumab or zoledronic acid, suggesting that the concomitant use of these therapy types is currently a common practice. Use of denosumab or zoledronic acid was higher in patients with verified bone metastases.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial completion date, Trial primary completion date:  Denosumab Treatment for Fibrous Dysplasia (clinicaltrials.gov) -  Apr 25, 2019   
    P2,  N=14, Enrolling by invitation, 
    Use of denosumab or zoledronic acid was higher in patients with verified bone metastases. Trial completion date: Jan 2020 --> Mar 2030 | Trial primary completion date: Jan 2020 --> Mar 2030
  • ||||||||||  Clinical, Journal:  Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases. (Pubmed Central) -  Apr 23, 2019   
    Patients were treated mainly with abiraterone across most lines of care, with radium-223, cabazitaxel, and mitoxantrone as the least utilized therapies. Median costs PPPM increased by approximately $8,900 after initiation of FDA-approved agents for mCRPC, with the largest increase in cost stemming from oral medications.
  • ||||||||||  Prolia (denosumab) / Amgen
    Enrollment open:  Denosumab for Smoldering Multiple Myeloma (clinicaltrials.gov) -  Apr 22, 2019   
    P2,  N=20, Recruiting, 
    Median costs PPPM increased by approximately $8,900 after initiation of FDA-approved agents for mCRPC, with the largest increase in cost stemming from oral medications. Not yet recruiting --> Recruiting
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Journal:  Hyperthyroidism-induced calciphylaxis: A case report (Pubmed Central) -  Apr 20, 2019   
    This is the first description of AUC secondary to hyperthyroidism in a dialysis patient. Multidisciplinary care is essential to achieve clinical improvement in those critical situations.
  • ||||||||||  Prolia (denosumab) / Amgen
    Biomarker, Trial completion, Trial completion date, Trial primary completion date:  Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=7, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Mar 2019 Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Oct 2018 | Trial primary completion date: Feb 2020 --> Oct 2018
  • ||||||||||  Prolia (denosumab) / Amgen
    New P4 trial:  Markers of Osteoporosis in Cystic Fibrosis (clinicaltrials.gov) -  Apr 18, 2019   
    P4,  N=100, Not yet recruiting, 
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial primary completion date:  Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis (clinicaltrials.gov) -  Apr 18, 2019   
    P3,  N=150, Recruiting, 
    The therapeutic role of bisphosphonates and denosumab to improve patient outcome deserves to be tested in a prospective clinical trial. Trial completion date: Apr 2026 --> Mar 2029 | Trial primary completion date: May 2023 --> Mar 2026
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Review, Journal:  Antibodies as treatment option in older adults (Pubmed Central) -  Apr 17, 2019   
    Particularly, with respect to sarcopenia the transition to "doping for older adults" seems to be fluent. The present review provides an overview on the newest developments and prospective options.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review. (Pubmed Central) -  Apr 12, 2019   
    To the best of knowledge, no study has attempted to summarize the related literature on the use of denosumab in ABCs. Therefore, the primary aim of this study is to narratively review all the available literature about the efficacy and safety of the use of off-label denosumab in the management of patients with ABCs.
  • ||||||||||  QL1206 (denosumab biosimilar) / Qilu Pharma
    Enrollment closed:  Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva (clinicaltrials.gov) -  Apr 11, 2019   
    P1,  N=168, Active, not recruiting, 
    To optimize therapeutic outcomes for patients, clinicians need to be aware of the complexity of factors affecting medication adherence. Recruiting --> Active, not recruiting
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial initiation date, Trial primary completion date:  Denosumab for Smoldering Multiple Myeloma (clinicaltrials.gov) -  Apr 10, 2019   
    P2,  N=20, Not yet recruiting, 
    Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Mar 2024 --> Jun 2024 | Initiation date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Journal:  Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice (Pubmed Central) -  Apr 9, 2019   
    Denosumab was effective in increasing BMD not only in untreated patients, but also in those who had previously received antiosteoporotic therapy. The pharmacokinetic characteristics of denosumab, which contribute to its uniform distribution in trabecular and cortical bone tissue, regardless of active bone remodeling, and the fact that the clearance of the drug is independent of kidney function offer an advantage of administering the drug to patients with significant loss of FN and radius BMD and of reducing kidney function.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial completion date, Trial initiation date, Trial primary completion date:  Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis (clinicaltrials.gov) -  Apr 8, 2019   
    P=N/A,  N=20, Not yet recruiting, 
    The pharmacokinetic characteristics of denosumab, which contribute to its uniform distribution in trabecular and cortical bone tissue, regardless of active bone remodeling, and the fact that the clearance of the drug is independent of kidney function offer an advantage of administering the drug to patients with significant loss of FN and radius BMD and of reducing kidney function. Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Jul 2019 --> Jan 2020 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
    Review, Journal:  Anabolic Therapies in Osteoporosis and Bone Regeneration. (Pubmed Central) -  Apr 5, 2019   
    The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims.